ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012
ASCO: dabrafenib/Trametinib active in metastatic melanoma

(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic melanoma, according to a study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Jeffrey S. Weber, M.D., M.P.H., from the H. Lee Moffitt Cancer Center in Tampa, Fla., and colleagues enrolled 125 patients with V600 BRAF-mutant solid tumors, including 77 patients with who had not received prior treatment with BRAF inhibitors. Patients were treated at four escalating dose levels of 75/1, 150/1, 150/1.5, and 150/2 (mg twice daily/mg once daily) of dabrafenib/trametinib, and safety and efficacy were assessed.

The researchers found that the overall response rate was 56 percent among the 77 melanoma patients. At ascending dose levels, the confirmed response rate was 67, 64, 48, and 54 percent, respectively. The overall progression-free survival (PFS) was 7.4 months. For the corresponding dose levels, the median PFS was 8.7, 8.3, and 5.5 months, with PFS not mature for the 150/2 dose level. Among the cohort of 125 patients, there were two grade 5 adverse events, pneumonia and hyponatremia; the most common grade 3/4 adverse events were pyrexia, fatigue, and dehydration. Grade 2 or higher skin toxicity was seen in 14 percent of patients. Cutaneous and actinic keratoses each occurred in 2 percent of patients.

"It's fascinating to find such promising effects with this combination regimen. Not only are the two drugs causing shrinkage of the cancer, but we're seeing that a second anti-cancer therapy may actually suppress the side effects of the first," Weber said in a statement.

Several authors disclosed to pharmaceutical companies, including GlaxoSmithKline, which manufactures dabrafenib/trametinib.

Explore further: Response rate high for some patients with metastatic melanoma treated with vemurafenib

More information: Abstract
More Information

Related Stories

Response rate high for some patients with metastatic melanoma treated with vemurafenib

March 16, 2012
An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase ...

New drug, Vemurafenib, doubles survival of metastatic melanoma patients

March 1, 2012
A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib – increasing median survival ...

New melanoma drug Zelboraf nearly doubles survival in majority of patients

February 22, 2012
Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival.

Second mutation in BRAF-mutated melanoma doesn't contribute to resistance

April 1, 2012
A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true.

Study identifies genes that may help predict response to BRAF inhibitors for advanced melanoma

June 1, 2011
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman ...

Recommended for you

Study provides insight into link between two rare tumor syndromes

August 22, 2017
UCLA researchers have discovered that timing is everything when it comes to preventing a specific gene mutation in mice from developing rare and fast-growing cancerous tumors, which also affects young children. This mutation ...

Retaining one normal BRCA gene in breast, ovarian cancers influences patient survival

August 22, 2017
Determining which cancer patients are likely to be resistant to initial treatment is a major research effort of oncologists and laboratory scientists. Now, ascertaining who might fall into that category may become a little ...

Study identifies miR122 target sites in liver cancer and links a gene to patient survival

August 22, 2017
A new study of a molecule that regulates liver-cell metabolism and suppresses liver-cancer development shows that the molecule interacts with thousands of genes in liver cells, and that when levels of the molecule go down, ...

Zebrafish larvae could be used as 'avatars' to optimize personalized treatment of cancer

August 21, 2017
Portuguese scientists have for the first time shown that the larvae of a tiny fish could one day become the preferred model for predicting, in advance, the response of human malignant tumors to the various therapeutic drugs ...

Scientists discover vitamin C regulates stem cell function, curbs leukemia development

August 21, 2017
Not much is known about stem cell metabolism, but a new study from the Children's Medical Center Research Institute at UT Southwestern (CRI) has found that stem cells take up unusually high levels of vitamin C, which then ...

Searching for the 'signature' causes of BRCAness in breast cancer

August 21, 2017
Breast cancer cells with defects in the DNA damage repair-genes BRCA1 and BRCA2 have a mutational signature (a pattern of base swaps—e.g., Ts for Gs, Cs for As—throughout a genome) known in cancer genomics as "Signature ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.